Commercial Operating System (COS)

Elektrofi Announces Collaboration with Thermo Fisher Scientific to Strengthen Manufacturing Capabilities for Future Clinical Trials

Retrieved on:

Tuesday, February 7, 2023

Health, Commercial Operating System (COS), Entrepreneurship, Caregiver, Hospital, CGMP, Therapy, Drug development, Norwich Pharma Services, Patient, Thermo Fisher Scientific, Medicine, Pharmaceutical industry

Based on strong preclinical validation and partner interest, the company expects to initiate multiple clinical trials in 2024.

Key Points:

Based on strong preclinical validation and partner interest, the company expects to initiate multiple clinical trials in 2024.
“To successfully initiate clinical development, we need to establish certified cGMP manufacturing capabilities.
“Our expertise in drug development and manufacturing will help Elektrofi pioneer a significant advance in how medicine is introduced into patients,” said Leon Wyszkowski, President, Commercial Operations, Pharma Services for Thermo Fisher Scientific.
“We deeply appreciate their confidence in us and look forward to the clinical research progress we will make together."

Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development

Retrieved on:

Monday, February 6, 2023

CINCINNATI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced the appointment of Frank Jaeger, seasoned commercial operations and business development executive, as Senior Vice President of Marketing and Business Development.

Key Points:

CINCINNATI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced the appointment of Frank Jaeger, seasoned commercial operations and business development executive, as Senior Vice President of Marketing and Business Development.
His background in R&D, Medical Affairs, Business Development, and throughout Commercial Operations provides a broad world view and an understanding of varying perspectives.
Mr. Jaeger has a wide range of specialty expertise across multiple disease areas, with substantial in-market experience on over 20 products.
As the Senior Vice President, Chief Commercial Officer, he created a high-performing leadership team and launched its first asset – JATENZO® in just over 4 months.

Regulatory filing for house dust mite allergy tablet accepted for review in China

Retrieved on:

Friday, February 3, 2023

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that its Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (AIT) tablet has been accepted for review by the National Medical Products Administration (NMPA) in China.

Key Points:

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that its Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (AIT) tablet has been accepted for review by the National Medical Products Administration (NMPA) in China.
The BLA, for treatment of persistent moderate-to-severe HDM allergic rhinitis in patients aged 12–65 was submitted in late December 2022.
The Chinese regulatory review process is anticipated to complete in 2024 so that, subject to approval, the wider market introduction could follow shortly hereafter.
For further information please contact:
This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

GTG to form Strategic Alliance with global testing leader QIAGEN

Retrieved on:

Wednesday, February 1, 2023

MELBOURNE, Australia, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to announce that the Company is forming a strategic alliance with QIAGEN, a global leader in molecular testing with operations in 35 countries.

Key Points:

MELBOURNE, Australia, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to announce that the Company is forming a strategic alliance with QIAGEN, a global leader in molecular testing with operations in 35 countries.
The partnership will further enhance GTG’s reputation as a regional leader in precision medicine in predicative and consumer genomics, utilizing QIAGEN technologies.
QIAGEN will support the Company through their global technical expertise and leadership, and work closely with GTG to bolster automation capability with hardware, reagents and panels, bringing best-in-class testing.
This strategic alliance will leverage QIAGEN testing technologies from Sample to Insight for multiple applications.

Safe & Green Holdings Corp. Announces the Addition of Rick Episcopo to Lead the Environmental Vertical Sales Team

Retrieved on:

Thursday, January 19, 2023

Safe & Green Holdings Corp. (NASDAQ: SGBX) (“Safe & Green Holdings” or the “Company”), a leading developer, designer, and fabricator of modular structures, announced today that the Company has engaged Rick Episcopo to support sales and business development efforts for Safe & Green Holdings Corp. Episcopo joins Safe & Green Holdings with an extensive background in sales and customer success from his previous roles in a variety of industries.

Key Points:

Safe & Green Holdings Corp. (NASDAQ: SGBX) (“Safe & Green Holdings” or the “Company”), a leading developer, designer, and fabricator of modular structures, announced today that the Company has engaged Rick Episcopo to support sales and business development efforts for Safe & Green Holdings Corp. Episcopo joins Safe & Green Holdings with an extensive background in sales and customer success from his previous roles in a variety of industries.
View the full release here: https://www.businesswire.com/news/home/20230119005315/en/
Safe & Green Holdings is excited to bring Episcopo on board to lead the build out of the sales pipeline in the Environmental vertical.
“The entire team is looking forward to learning from Episcopo’s experience working with customers and building successful relationships to foster partnerships,” Paul Galvin, Chairman and CEO of Safe & Green Holdings Corp., explained.
Episcopo became the CEO of Genomics Collaborative in early 2004 and successfully sold the company to SeraCare Life Sciences later that year.

iBwave Simplifies Public Safety Network Testing & Verification with Epiq PRiSM scanner and new Grid Test Functionality

Retrieved on:

Wednesday, January 18, 2023

iBwave Solutions , the industry-leading software provider for wireless network design, today announced the immediate availability of an updated version for its Public Safety survey solution, further advancing the network testing and verification capabilities offered by the existing iBwave Mobile Survey application and robust handheld Epiq PRiSM scanner.

Key Points:

iBwave Solutions , the industry-leading software provider for wireless network design, today announced the immediate availability of an updated version for its Public Safety survey solution, further advancing the network testing and verification capabilities offered by the existing iBwave Mobile Survey application and robust handheld Epiq PRiSM scanner.
The new grid test capabilities combined with the existing iBwave Public safety desktop offering gives public safety engineers the complete solution they need to test, verify, design and document public safety networks that meet the latest in U.S. standards and regulations.
The latest version of the iBwave Public Safety Solution, which includes the iBwave Mobile survey with the Epiq PRiSM scanner integration and the powerful Public Safety network design desktop software includes:
Seamless integration with the easy-to-use, affordable and lightweight Epiq PRiSM Scanner for use in public safety P25 surveys and grid testing.
New ‘Grid Test’ Module in the iBwave Mobile survey app for testing, verifying and generating grid test pass/fail reports for submission to AHJs (Authorities Having Jurisdiction) in the U.S.

FirstLight Power and Reading Municipal Light Department Enter Power Purchase Agreement for all the Output of the Falls Village Hydro Facility

Retrieved on:

Wednesday, January 18, 2023

Alternative Energy, Energy, State, Local, Public Policy, Government, Utilities, Natural gas, Housatonic River, Commonwealth, Geography, Senior, ENE, Risk management, Commercial Operating System (COS), Firstlight Media, Electricity, Renewable energy

FirstLight Power, a leading clean provider of renewable energy and energy storage resources, today announced the extension of the company’s power purchase agreement with Reading Municipal Light Department (RMLD).

Key Points:

FirstLight Power, a leading clean provider of renewable energy and energy storage resources, today announced the extension of the company’s power purchase agreement with Reading Municipal Light Department (RMLD).
“We are thrilled to extend our collaboration with the Reading Municipal Light Department, which will help deliver clean, reliable, and cost-competitive electricity to RMLD ratepayers,” said Peter Rider, Senior Vice President of Commercial Operations of FirstLight Power.
As part of the agreement with RMLD, FirstLight’s Falls Village Station, which is located in Falls Village, CT, will supply the municipality with energy and renewable energy credits.
Falls Village is a three-unit hydroelectric station on the Housatonic River and the facility is qualified as a Class I (CT Class I) renewable run-of-river energy facility.

Siteimprove Expands Global Leadership Team to Bolster Company Growth

Retrieved on:

Tuesday, January 17, 2023

Digital Marketing, Search Engine Optimization, Search Engine Marketing, Public Relations, Investor Relations, Marketing, Content Marketing, Advertising, Communications, DeLoach, Commercial Operating System (COS), Growth, APJ, Product marketing, Education, Senior, Management, Siteimprove, Global Sales Law Project

Siteimprove , the leading platform that empowers brands to stand out with engaging, accessible, and high-performing digital content experiences, today announced key appointments to its growing executive leadership team.

Key Points:

Siteimprove , the leading platform that empowers brands to stand out with engaging, accessible, and high-performing digital content experiences, today announced key appointments to its growing executive leadership team.
In her new role, Misiorny will lead the global marketing team focused on driving brand awareness, product positioning and demand generation for Siteimprove’s state of the art marketing solutions worldwide.
In addition to the appointment of Misiorny and DeLoach, Siteimprove is also expanding its commercial leadership team.
With this combination of experienced and results-oriented commercial leaders, Siteimprove will continue to rapidly accelerate its scale and growth.

Novavax Names John C. Jacobs as New President & Chief Executive Officer

Retrieved on:

Monday, January 9, 2023

"Stan led Novavax from a clinical development organization to a global commercial vaccines company during a worldwide pandemic.

Key Points:

"Stan led Novavax from a clinical development organization to a global commercial vaccines company during a worldwide pandemic.
This foundation puts Novavax in a strong position to execute on its long-term strategy, and we look forward to supporting Stan and John through the transition.
John is a seasoned industry leader who will bring a fresh perspective and deep industry expertise to Novavax."
He will join Novavax from Harmony Biosciences, where he has served as President and Chief Executive Officer and a member of the Board of Directors since June 2018, and Executive Vice President and Chief Commercial Officer from October 2017 to June 2018.

JUNO DIAGNOSTICS™ EXPANDS ITS PRODUCT PORTFOLIO WITH THE LAUNCH OF JUNO HAZEL™ PLUS AND ANNOUNCES EARLY ACCESS PROGRAM (EAP) FOR INNOVATIVE NIPS TESTS

Retrieved on:

Monday, January 9, 2023

Similar to the Juno Hazel™ screening test, Juno Hazel™ Plus leverages JunoDx's proprietary Sample Collection Kit to improve early access to high-quality genetic testing without the high costs, long lead times, and phlebotomy requirements of venous-based NIPS.

Key Points:

Similar to the Juno Hazel™ screening test, Juno Hazel™ Plus leverages JunoDx's proprietary Sample Collection Kit to improve early access to high-quality genetic testing without the high costs, long lead times, and phlebotomy requirements of venous-based NIPS.
Juno Hazel™ Plus offers a comprehensive prenatal screening solution by screening for common chromosomal trisomies, sex chromosome aneuploidies, and fetal sex.
"The expansion of our product portfolio with the launch of our second NIPS test , Juno Hazel™ Plus, represents a significant milestone for JunoDx™.
To ensure every pregnancy has the opportunity to benefit from our product portfolio, the time is now to create and launch a formalized Early Access Program.